523 related articles for article (PubMed ID: 36899824)
1. Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID.
Theoharides TC; Kempuraj D
Cells; 2023 Feb; 12(5):. PubMed ID: 36899824
[TBL] [Abstract][Full Text] [Related]
2. Recombinant SARS-CoV-2 Spike Protein and Its Receptor Binding Domain Stimulate Release of Different Pro-Inflammatory Mediators via Activation of Distinct Receptors on Human Microglia Cells.
Tsilioni I; Theoharides TC
Mol Neurobiol; 2023 Nov; 60(11):6704-6714. PubMed ID: 37477768
[TBL] [Abstract][Full Text] [Related]
3. Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?
Theoharides TC
Mol Neurobiol; 2022 Mar; 59(3):1850-1861. PubMed ID: 35028901
[TBL] [Abstract][Full Text] [Related]
4. Mast cell activation triggered by SARS-CoV-2 causes inflammation in brain microvascular endothelial cells and microglia.
Wu ML; Xie C; Li X; Sun J; Zhao J; Wang JH
Front Cell Infect Microbiol; 2024; 14():1358873. PubMed ID: 38638822
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Spike Targets USP33-IRF9 Axis
Mishra R; Banerjea AC
Front Immunol; 2021; 12():656700. PubMed ID: 33936086
[TBL] [Abstract][Full Text] [Related]
6. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Spike Protein Destabilizes Microvascular Homeostasis.
Panigrahi S; Goswami T; Ferrari B; Antonelli CJ; Bazdar DA; Gilmore H; Freeman ML; Lederman MM; Sieg SF
Microbiol Spectr; 2021 Dec; 9(3):e0073521. PubMed ID: 34935423
[TBL] [Abstract][Full Text] [Related]
8. Blood-brain barrier function in response to SARS-CoV-2 and its spike protein.
Suprewicz Ł; Fiedoruk K; Czarnowska A; Sadowski M; Strzelecka A; Galie PA; Janmey PA; Kułakowska A; Bucki R
Neurol Neurochir Pol; 2023; 57(1):14-25. PubMed ID: 36810757
[TBL] [Abstract][Full Text] [Related]
9. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae.
Swank Z; Senussi Y; Manickas-Hill Z; Yu XG; Li JZ; Alter G; Walt DR
Clin Infect Dis; 2023 Feb; 76(3):e487-e490. PubMed ID: 36052466
[TBL] [Abstract][Full Text] [Related]
10. Recombinant SARS-CoV-2 Spike Protein Stimulates Secretion of Chymase, Tryptase, and IL-1β from Human Mast Cells, Augmented by IL-33.
Tsilioni I; Theoharides TC
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298438
[TBL] [Abstract][Full Text] [Related]
11. The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection.
Moghimi N; Di Napoli M; Biller J; Siegler JE; Shekhar R; McCullough LD; Harkins MS; Hong E; Alaouieh DA; Mansueto G; Divani AA
Curr Neurol Neurosci Rep; 2021 Jun; 21(9):44. PubMed ID: 34181102
[TBL] [Abstract][Full Text] [Related]
12. Mast cells promote viral entry of SARS-CoV-2 via formation of chymase/spike protein complex.
Liu S; Suzuki Y; Takemasa E; Watanabe R; Mogi M
Eur J Pharmacol; 2022 Sep; 930():175169. PubMed ID: 35921955
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties.
Frank MG; Nguyen KH; Ball JB; Hopkins S; Kelley T; Baratta MV; Fleshner M; Maier SF
Brain Behav Immun; 2022 Feb; 100():267-277. PubMed ID: 34915155
[TBL] [Abstract][Full Text] [Related]
14. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
Choudhury A; Mukherjee S
J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Infection of Human Neurons Is TMPRSS2 Independent, Requires Endosomal Cell Entry, and Can Be Blocked by Inhibitors of Host Phosphoinositol-5 Kinase.
Kettunen P; Lesnikova A; Räsänen N; Ojha R; Palmunen L; Laakso M; Lehtonen Š; Kuusisto J; Pietiläinen O; Saber SH; Joensuu M; Vapalahti OP; Koistinaho J; Rolova T; Balistreri G
J Virol; 2023 Apr; 97(4):e0014423. PubMed ID: 37039676
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
17. Possible Link between SARS-CoV-2 Infection and Parkinson's Disease: The Role of Toll-Like Receptor 4.
Conte C
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281186
[TBL] [Abstract][Full Text] [Related]
18. Exploring the immunogenic properties of SARS-CoV-2 structural proteins: PAMP:TLR signaling in the mediation of the neuroinflammatory and neurologic sequelae of COVID-19.
Frank MG; Fleshner M; Maier SF
Brain Behav Immun; 2023 Jul; 111():259-269. PubMed ID: 37116592
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells.
Suzuki YJ; Nikolaienko SI; Dibrova VA; Dibrova YV; Vasylyk VM; Novikov MY; Shults NV; Gychka SG
Vascul Pharmacol; 2021 Apr; 137():106823. PubMed ID: 33232769
[TBL] [Abstract][Full Text] [Related]
20. Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19.
Craddock V; Mahajan A; Spikes L; Krishnamachary B; Ram AK; Kumar A; Chen L; Chalise P; Dhillon NK
J Med Virol; 2023 Feb; 95(2):e28568. PubMed ID: 36756925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
